Accelerated Approval Now Starting Point For Gene Therapy Development, US FDA’s Marks Says
Executive Summary
Expedited approval pathway had been a secondary option when traditional approval was not possible, but the CBER director wants surrogate endpoints increasingly considered from the beginning, especially with pediatric rare disease gene therapies.